Drug Trial Radar · NCT04774718
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Sep 14, 2021
Primary completion
Feb 28, 2032
Study completion Feb 28, 2032
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Conditions
- ALK Fusion-positive Solid or CNS Tumors
Interventions
AlectinibDrug
Participants will receive twice-daily alectinib capsules on Days 1-28 of each 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Participants with Dose-Limited Toxicities (DLTs)Time frame: Cycle 1 (cycle length = 28 days)
- Percentage of Participants with Adverse EventsTime frame: Up to 10 years
- Plasma Concentration of AlectinibTime frame: Up to 10 years
- Plasma Concentration of Alectinib Metabolite (M4)Time frame: Up to 10 years
- Confirmed Objective Response Rate (ORR): Defined as the Proportion of Participants with Complete Response (CR) or Partial Response (PR) on two Consecutive Occasions >/= 4 Weeks Apart, as Determined by Blinded Independent Central Review (BICR)Time frame: Up to 10 years
Locations
30 sites in 11 countries. Site status is shown where the registry gives one.
Lucile Packard Children's Hospital
Palo Alto, California
Johns Hopkins All Children's Hospital
St. Petersburg, Florida
University of Michigan, C.S. Mott Children's Hospital
Ann Arbor, Michigan
Children's Minnesota
Minneapolis, Minnesota
Memorial Sloan Kettering Cancer Center
New York, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
St. Jude Children'S Research Hospital
Memphis, Tennessee
Sydney Children's Hospital
Randwick, New South Wales, Australia
Royal Children's Hospital
Parkville, Victoria, Australia
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Graacc-Grupo de Apoio ao adolescente e a crianca com cancer
São Paulo, São Paulo, Brazil
The Hospital for Sick Children
Toronto, Ontario, Canada
CHU Sainte-Justine
Montreal, Quebec, Canada
Beijing Children's Hospital, Capital Medical University
Beijing, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
Rigshospitalet
København Ø, Denmark
Centre Léon Bérard, Institut d?Hémato-Oncologie Pédiatrique
Lyon, France
Hôpital de la Timone, Oncologie Pédiatrique
Marseille, France
Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris
Paris, France
Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS
Genoa, Liguria, Italy
Istituto Nazionale Tumori di Milano
Milan, Lombardy, Italy
Dipartimento di Scienze Pediatriche Adolescenza
Turin, Piedmont, Italy
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Hospital Infantil Universitario Nino Jesus
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Great Ormond Street Hospital
London, United Kingdom
Royal Manchester Childrens Hospital
Manchester, United Kingdom
Great North Children's Hospital
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.